Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab Combined With Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07064902Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2026
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07064902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07064902.